Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The mechanism by which mutations in the presenilin (PS) genes cause the most aggressive form of early-onset Alzheimer's disease (AD) is unknown, but fibroblasts from mutation carriers secrete increased levels of the amyloidogenic A beta 42 peptide, the main component of AD plaques. We established transfected cell and transgenic mouse models that coexpress human PS and amyloid beta-protein precursor (APP) genes and analyzed quantitatively the effects of PS expression on APP processing. In both models, expression of wild-type PS genes did not alter APP levels, alpha- and beta-secretase activity and A beta production. In the transfected cells, PS1 and PS2 mutations caused a highly significant increase in A beta 42 secretion in all mutant clones. Likewise, mutant but not wildtype PS1 transgenic mice showed significant overproduction of A beta 42 in the brain, and this effect was detectable as early as 2-4 months of age. Different PS mutations had differential effects on A beta generation. The extent of A beta 42 increase did not correlate with presenilin expression levels. Our data demonstrate that the presenilin mutations cause a dominant gain of function and may induce AD by enhancing A beta 42 production, thus promoting cerebral beta-amyloidosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies have shown that mice coexpressing FAD mutant APP and PS1 transgenes exhibit additive increases in A 𝛃 42 production (Borchelt et al., 1996, 1997; Citron et al., 1997; Holcomb et al., 1998), althoughrarely have more than two A 𝛃 42 -elevating FAD mutations been combined in transgenic animals.”
From Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation (2006) · cites this paper as Citron et al., 1997
In the citing paper
“each of these genetic forms of AD either selectively increases the extracellular concentration of A42 (Suzuki et al., 1994;Borchelt et al., 1996;Duff et al., 1996;Scheuner et al., 1996;Citron et al., 1997) or increases both A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Citron et al., 1997
In the citing paper
“familial EOAD mutations in PSEN1 and PSEN2 typically result in an increased production of longer and more aggregation-prone derivatives of APP such as Aβ1–42 [47–49].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [47]
Citations
Cites
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Self-citationRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citationEndoproteolysis of Presenilin 1 and Accumulation of Processed Derivatives In Vivo
Thinakaran, G., Borchelt, D. R., Lee, M. K., Slunt, H. H., Spitzer, L., Kim, G., Ratovitsky, T., Davenport, F., Nordstedt, C., Seeger, M., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80291-3 · Cited by 1,013
Self-citationPrusiner, S. B., Scott, M., Foster, D., Pan, K.-M., Groth, D., Mirenda, C., Torchia, M., Yang, S.-L., Serban, D., Carlson, G. A., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90134-z · Cited by 871
Self-citationAmyloid β-Protein and the Genetics of Alzheimer's Disease
Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18295 · Cited by 799
Self-citationRadzicka, A., & Wolfenden, R. (1988) · Biochemistry · doi:10.1021/bi00405a042 · Cited by 606
Cited by
Items 601–700 of 1,002
Decreased level of brain acetylcholine and memory disturbance in APPsw mice
Ikarashi, Y., Harigaya, Y., Tomidokoro, Y., Kanai, M., Ikeda, M., Matsubara, E., Kawarabayashi, T., Kuribara, H., Younkin, S. G., Maruyama, Y., et al. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00122-2 · Cited by 46
“Since all mutations in these genes increase the extracellular concentration of A 40 and/or A 42(43) in cultured cells, fibroblasts or plasma from patients and transgenic (Tg) mice expressing FAD-linked mutants [4,8,12,43],”
BackgroundGenetic complexity of Alzheimer's disease: Successes and challenges
Rogaeva, E., Kawarai, T., & George-Hyslop, P. S. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s343 · Cited by 46
“MutationsinthePS1andPS2 genes cause the over-production of A β 42 , which further supports the concept that changes in A β PP processing are central to AD pathology [6].”
Mechanisms of synaptic pathology in Alzheimer’s disease
Masliah, E. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6467-9_13 · Cited by 51
Refolo, L. M., Eckman, C., Prada, C.-M., Yager, D., Sambamurti, K., Mehta, N. D., Hardy, J., & Younkin, S. G. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0732383.x · Cited by 46
“First, mutations in PS1 lead to increased synthesis of Ab42 (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997; Holcomb et al., 1998; Mehta et al., 1998), suggesting that these mutations result in an increased amyloidogenic processing of APP.”
InfluentialRecent Advances in the Genetics of Alzheimer's Disease
Levy‐Lahad, E., Tsuang, D. W., & Bird, T. D. (1998) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879801100202 · Cited by 50
Gold, G., Blouin, J., Herrmann, F. R., Michon, A., Mulligan, R., Saïl, G. D., Bouras, C., Giannakopoulos, P., & Antonarakis, S. E. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.10010 · Cited by 48
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Jakobsen, J. E., Johansen, M. G., Schmidt, M., Liu, Y., Li, R., Callesen, H., Melnikova, M., Habekost, M., Matrone, C., Bouter, Y., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160408 · Cited by 46
“…of A (cid:2) 42 andA (cid:2) 40 inthehippocampaltissue(Table1)detected a slight increase in total A (cid:2) and in the A (cid:2) 42 /A (cid:2) 40 ratio in the double-transgenics, which is consistent with the predicted combined effect of A (cid:2) PP Swedish and PSEN1 M146I mutations [17, 48–50].”
Self-citationLiu, L., Lauro, B. M., He, A., Lee, H., Bhattarai, S., Wolfe, M. S., Bennett, D. A., Karch, C. M. M., Young‐Pearse, T. L., Dominantly Inherited Alzheimer Network (DIAN), et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12646 · Cited by 52
Self-citationSaiz-Sanchez, D., Ubeda-Bañon, I., De la Rosa-Prieto, C., & Martinez-Marcos, A. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111889 · Cited by 45
“FADlinked mutant forms of A PP and PS1 are thought to increase A levels [60] and to enhance the vulnerability of neurons [49]; it was therefore anticipated that the use of homozygous animals would lead to early pathology, thereby permitting the study of interneuron populations and A accumulation very early in the deve…”
BackgroundLesuisse, C., Xu, G., Anderson, J., Wong, M., Jankowsky, J., Holtz, G., Gonzalez, V., Wong, P. C., Price, D. L., Tang, F., et al. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.22.2525 · Cited by 49
Alzheimer's presenilin 1 is a putative membrane receptor for rab GDP dissociation inhibitor
Scheper, W., Zwart, R., van der Sluijs, P., Annaert, W., Gool, W. A., & Baas, F. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.2.303 · Cited by 52
De Jonghe, C., Cras, P., Vanderstichele, H., Cruts, M., Vanderhoeven, I., Smouts, I., Vanmechelen, E., Martin, J.-J., Hendriks, L., & Van Broeckhoven, C. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0247 · Cited by 45
Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease
Li, C., Ebrahimi, A., & Schluesener, H. J. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.09.002 · Cited by 50
Tautomeric Effect of Histidine on the Monomeric Structure of Amyloid β-Peptide(1–42)
Shi, H., & Lee, J. Y. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00375 · Cited by 44
Tiscione, S. A., Vivas, O., Ginsburg, K. S., Bers, D. M., Ory, D. S., Santana, L. F., Dixon, R. E., & Dickson, E. J. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201903018 · Cited by 45
“Due to its low abundance and short half-life (Ratovitski et al., 1997), we, like others (Walter et al., 1996; Citron et al., 1997; Ratovitski et al., 1997), failed to detect a holoprotein band in patient fibroblasts.”
BackgroundSuccessive cleavage of β-amyloid precursor protein by γ-secretase
Funamoto, S., Tagami, S., Okochi, M., & Morishima‐Kawashima, M. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.04.002 · Cited by 48
Schenk, D., Games, D., & Seubert, P. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:259 · Cited by 47
“This finding again implicates the role of Aβ in the pathogenesis of the AD (Citron et al., 1997; Duff et al., 1996; Lemere et al., 1996).”
BackgroundSelf-citationClarke, E. E., & Shearman, M. S. (2000) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(00)00280-6 · Cited by 45
From Soluble A β to Progressive A β Aggregation: Could Prion‐Like Templated Misfolding Play a Role?
Eisele, Y. S. (2013) · Brain Pathology · doi:10.1111/bpa.12049 · Cited by 48
“These mutations lead to subtle changes in APP metabolism with increased production of Ab peptides and/or to generation of more aggregation prone variants (7, 12, 16, 19, 20, 52, 76).”
BackgroundMembrane cholesterol enrichment prevents Aβ-induced oxidative stress in Alzheimer's fibroblasts
Pensalfini, A., Zampagni, M., Liguri, G., Becatti, M., Evangelisti, E., Fiorillo, C., Bagnoli, S., Cellini, E., Nacmias, B., Sorbi, S., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.02.010 · Cited by 43
Strazielle, C., Jazi, R., Verdier, Y., Qian, S., & Lalonde, R. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.08.005 · Cited by 44
Lin, H.-C., Ho, M., Tsen, C.-M., Huang, C.-C., Wu, C.-C., Huang, Y.-J., Hsiao, I., & Chuang, C. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx079 · Cited by 43
TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis
Palomo, V., Tosat‐Bitrián, C., Nozal, V., Nagaraj, S., Martín‐Requero, Á., & Martínez, A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00026 · Cited by 48
An Update on the Amyloid Hypothesis
Eckman, C. B., & Eckman, E. A. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.007 · Cited by 51
“These elevations can be detected in plasma and in fibroblast-conditioned medium isolated from presymptomatic individuals [36,48] and in transgenic animals before deposition [49,50], suggesting that these changes are early and not simply an epiphenomenon associated with end-stage AD.”
BackgroundLawford‐Smith, H. (2015) · Journal of Social Ontology · doi:10.1515/jso-2015-0008 · Cited by 59
Kölsch, H., Ptok, U., Mohamed, I., Schmitz, S., Rao, M. L., Maier, W., & Heun, R. (2003) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20043 · Cited by 43
“Mutations of the genes encoding the b-amyloid precursor protein, and the presenilins 1 and 2 are risk-factors for the early-onset AD [Citron et al., 1997; Goate, 1998].”
BackgroundPresenilin and γ‐secretase: structure meets function
Wolfe, M. S. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00245.x · Cited by 49
“Overexpression of wild-type presenilin, however, does not lead to increased g-secretase activity (Citron et al. 1997).”
BackgroundThe Maze of APP Processing in Alzheimer’s Disease: Where Did We Go Wrong in Reasoning?
Chen, M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00186 · Cited by 46
“Why Presenilins are Unlikely to be “γ-Secretase” At the same time, it has also been claimed that “γ-secretase” is identified as presenilins (PS1 and PS2) with the active center at D257 or D385 in PS1 (Citron et al., 1997; Wolfe et al., 1999).”
Transmembrane Substrate Determinants for γ-Secretase Processing of APP CTFβ
Fernandez, M. A., Biette, K. M., Dolios, G., Seth, D., Wang, R., & Wolfe, M. S. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00718 · Cited by 41
Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's disease
Bera, A., Lavanya, G., Reshmi, R., Dev, K., & Kumar, R. K. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15611 · Cited by 44
Pro198Leu polymorphism affects the selenium status and GPx activity in response to Brazil nut intake
Cardoso, B. R., Busse, A. L., Hare, D. J., Cominetti, C., Horst, M. A., McColl, G., Magaldi, R. M., Filho, W. J., & Cozzolino, S. M. F. (2015) · Food & Function · doi:10.1039/c5fo01270h · Cited by 44
Wolvetang, E. W., Bradfield, O. M., Tymms, M., Zavarsek, S., Hatzistavrou, T., Kola, I., & Hertzog, P. J. (2003) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(03)00121-0 · Cited by 41
LDL receptor-related protein (LRP) in Alzheimer's disease: Towards a unified theory of pathogenesis
Van Uden, E., Kang, D. E., Koo, E. H., & Masliah, E. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20000815)50:4<268::aid-jemt3>3.0.co;2-1 · Cited by 42
2023 China Alzheimer’s disease: facts and figures
Xiao, J., Li, J., Wang, J., Zhang, X., Wang, C., Peng, G., Hu, H., Liu, H., Liu, J., Shen, L., et al. (2023) · Human Brain · doi:10.37819/hb.3.1771 · Cited by 47
Ratnayaka, J. A., Lynn, S. A., Keeling, E., Munday, R., Gabha, G., Griffiths, H., & Lotery, A. J. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.205083 · Cited by 41
“…cell membrane integrity (Williams et al., 2010), altering neuronal long-term potentiation (Townsend et al., 2006), inducing synaptic loss (Lacor et al., 2007; Shankar et al., 2007) as well as inducing memory defects in animal models (Duff et al., 1996; Citron et al., 1997) amongst others.”
BackgroundDie Alzheimer‐Demenz: von der Pathologie zu therapeutischen Ansätzen
Jakob‐Roetne, R., & Jacobsen, H. (2009) · Angewandte Chemie · doi:10.1002/ange.200802808 · Cited by 41
Le Bastard, N., Aerts, L., Sleegers, K., Martin, J.-J., Van Broeckhoven, C., De Deyn, P. P., & Engelborghs, S. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-110029 · Cited by 42
“6 months; range: 2–43 months In-house ELISA A 1-42 [61] = ↑ ND ND”
BackgroundDevi, G., Fotiou, A., Jyrinji, D., Tycko, B., DeArmand, S., Rogaeva, E., Song, Y.-Q., Medieros, H., Liang, Y., Orlacchio, A., et al. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1454 · Cited by 41
“Despite being distinct from the immediate regulatory and coding regions of the gene encoding the APP, mutations in the PS1 gene can lead to cerebral amyloidogenesis and familial AD by promoting a relative overproduction of longer isoforms of the amyloid b peptide.(26) Compared with sporadic disease, AD associated with…”
BackgroundPresenilin 1 Independently Regulates β-Catenin Stability and Transcriptional Activity
Killick, R., Pollard, C. C., Asuni, A. A., Mudher, A. K., Richardson, J. C., Rupniak, H. T., Sheppard, P. W., Varndell, I. M., Brion, J.-P., Levey, A. I., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108332200 · Cited by 41
Monogenetic determinants of Alzheimer's disease: APP mutations
Goate, A. (1998) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050218 · Cited by 43
Amyloid, Presenilins, and Alzheimer’s Disease
Gassen, G. V., & Annaert, W. (2003) · The Neuroscientist · doi:10.1177/1073858403252227 · Cited by 41
A Lifespan Observation of a Novel Mouse Model: In Vivo Evidence Supports Aβ Oligomer Hypothesis
Zhang, Y., Lu, L., Jia, J., Jia, L., Geula, C., Pei, J., Xu, Z., Qin, W., Liu, R., Li, D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085885 · Cited by 40
Cellular Cofactors for Amyloid β-Peptide-Induced Cell Stress
Yan, S. D., Roher, A., Schmidt, A. M., & Stern, D. M. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65452-1 · Cited by 39
Brain Expression of Presenilins in Sporadic and Early-onset, Familial Alzheimer’s Disease
Mathews, P. M., Cataldo, A. M., Kao, B. H., Rudnicki, A., Qin, X., Yang, J. L., Jiang, Y., Picciano, M., Hulette, C., Lippa, C. F., et al. (2000) · Molecular Medicine · doi:10.1007/bf03401825 · Cited by 40
Self-citationPetanceska, S. S., Seeger, M., Checler, F., & Gandy, S. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741878.x · Cited by 32
“Mutant PS1 also elevates levels of Ab42 in the brains of transgenic mice (Borchelt et al., 1996; Duff et al., 1996; Citron et al., 1997; Holcomb et al., 1998).”
BackgroundEndoproteolysis of Presenilin in Vitro: Inhibition by γ-Secretase Inhibitors
Campbell, W. A., Iskandar, M.-K., Reed, M. L. O., & Xia, W. (2002) · Biochemistry · doi:10.1021/bi015810h · Cited by 42
Self-citationMa, D., Stokes, K., Mahngar, K., Domazet-Damjanov, D., Sikorska, M., & Pandey, S. (2014) · Mitochondrion · doi:10.1016/j.mito.2014.07.004 · Cited by 39
“The transmembrane protein PS-1 in particular, responsible for the development of AD familial type 3 when its gene is mutated, is a component of the γ-secretase complex responsible for APP processing to the amyloid-beta peptide (Aβ) (Citron et al., 1997; De Strooper et al., 1998).”
BackgroundFišar, Z., Jirák, R., Zvěřová, M., Setnička, V., Habartová, L., Hroudová, J., Vaníčková, Z., & Raboch, J. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.04.003 · Cited by 39
Neuroinflammatory Cytokines - The Common Thread in Alzheimer Pathogenesis
Griffin, W. S. T., Barger, S. W., Chairman, D. P. A. V., Professor of Geriatrics, N. A. D. S. A. I. M., & Professor of Geriatrics, N. A. D. S. A. I. M. (2011) · European Neurological Review · doi:10.17925/enr.2011.06.02.89 · Cited by 39
Keller, L., Welander, H., Chiang, H., Tjernberg, L. O., Nennesmo, I., Wallin, Å. K., & Graff, C. (2010) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.107 · Cited by 40
Immunotherapeutic approaches for Alzheimer’s disease in transgenic mouse models
Wısnıewskı, T., & Boutajangout, A. (2009) · Brain Structure and Function · doi:10.1007/s00429-009-0236-2 · Cited by 40
“PS is part of the c-secretase complex and FAD linked mutations are associated with an increase in Ab42 production (Borchelt et al. 1996; Citron et al. 1997; Wolfe 2009).”
BackgroundHOOK, V. Y. H., & Reisine, T. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10784 · Cited by 40
“These mutations appear to selectively enhance production of A (1–42) in AD brains and in transgenic mice (Duff et al., 1996; Borchelt et al., 1996; Citron et al., 1997; Weidemann et al., 1997; Xia et al., 1997; Holcomb et al., 1998).”
BackgroundPresenilin-1 interacts directly with the β-site amyloid protein precursor cleaving enzyme (BACE1)
Hébert, S. S., Bourdages, V., Godin, C., Ferland, M., Carreau, M., & Lévesque, G. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00035-4 · Cited by 39
Alzheimer’s Disease: Genes, Pathogenesis and Risk Prediction
Sleegers, K., & van Duijn, C. M. (2001) · Public Health Genomics · doi:10.1159/000064193 · Cited by 38
Kontush, A., Donarski, N., & Beisiegel, U. (2001) · Free Radical Research · doi:10.1080/10715760100301521 · Cited by 39
Coughlan, C. M., & Breen, K. C. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00036-x · Cited by 44
Thaker, U., McDonagh, A. M., Iwatsubo, T., Lendon, C. L., Pickering‐Brown, S. M., & A. Mann, D. M. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00425.x · Cited by 39
Inhibiting Amyloid Precursor Protein C-terminal Cleavage Promotes an Interaction with Presenilin 1
Verdile, G., Martins, R. N., Duthie, M., Holmes, E., George‐Hyslop, P. S., & Fraser, P. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000208200 · Cited by 43
Self-citationAtwood, C., & Bowen, R. L. (2015) · Hormones and Behavior · doi:10.1016/j.yhbeh.2015.06.021 · Cited by 41
Davidsson, P., Bogdanović, N., Lannfelt, L., & Blennow, K. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051266 · Cited by 40
Chinese Presenilin-1 V97L mutation enhanced Aβ42 levels in SH-SY5Y neuroblastoma cells
Fang, B., Jia, L., & Jia, J. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.06.072 · Cited by 40
Butterfield, D. A., & Owen, J. B. (2010) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201000070 · Cited by 39
Molecular Pathology of Alzheimer’s Disease and Related Disorders
Ginsberg, S. D., Schmidt, M. L., Crino, P. B., Eberwine, J. H., Lee, V. M. ‐., & Trojanowski, J. Q. (1999) · Cerebral cortex · doi:10.1007/978-1-4615-4885-0_17 · Cited by 39
Chen, F., Tandon, A., Sanjo, N., Gu, Y., Hasegawa, H., Arawaka, S., Lee, F. J. S., Ruan, X., Mastrangelo, P., Erdebil, S., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210049200 · Cited by 39
Self-citationAge-related changes in the localization of presenilin-1 in cynomolgus monkey brain
Kimura, N., Nakamura, S., Honda, T., Takashima, A., Nakayama, H., Ono, F., Sakakibara, I., Doi, K., Kawamura, S., & Yoshikawa, Y. (2001) · Brain Research · doi:10.1016/s0006-8993(01)03146-8 · Cited by 40
Hartmann, J., Erb, C., Ebert, U., Baumann, K., Popp, A., König, G., & Klein, J. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.02.038 · Cited by 41
Induction of TGF-β1 by the matricellular protein SPARC in a rat model of glomerulonephritis
Bassuk, J. A., Pichler, R. H., Rothmier, J. D., Pippen, J., Gordon, K., Meek, R. L., Bradshaw, A. D., Lombardi, D. M., Strandjord, T. P., Reed, M. J., et al. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00811.x · Cited by 38
AML1 haploinsufficiency, gene dosage, and the predisposition to acute leukemia
Barton, K., & Nucifora, G. (2000) · BioEssays · doi:10.1002/(sici)1521-1878(200003)22:3<214::aid-bies2>3.0.co;2-i · Cited by 20
Köhler, C., Ebert, U., Baumann, K., & Schröder, H. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.04.009 · Cited by 37
Can insulin signaling pathways be targeted to transport Aβ out of the brain?
Vandal, M., Bourassa, P., & Calon, F. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00114 · Cited by 41
“…the risk of AD (Goate et al., 1991; Rogaev et al., 1995; Sherrington et al., 1995; Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997), while a mutation more recently found to reduce Aβ production was rather associated with reduced AD incidence (Jonsson et al.,…”
Defective Autophagy and Mitophagy in Alzheimer’s Disease: Mechanisms and Translational Implications
Chen, J., He, H., Ye, Q., Feng, F., Wang, W., Gu, Y., Han, R., & Xie, C. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02487-7 · Cited by 37
Exploring Alzheimer's Disease in Zebrafish
Xia, W. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1412 · Cited by 38
Self-citationWrigley, J. D. J., Schurov, I., Nunn, E. J., Martin, A. C. L., Clarke, E. E., Ellis, S., Bonnert, T. P., Shearman, M. S., & Beher, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m413086200 · Cited by 38
Roses, A. D. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.153 · Cited by 39
“…with a rare early-onset form of the disease (Strittmatter et al, 1993; Schmechel et al, 1988; Bahmanyar et al, 1987; Goldgaber et al, 1987; Goate et al, 1991; St George-Hyslop et al, 1987; Tanzi et al, 1987; Citron et al, 1997; Sherrington et al, 1996; Kamino et al, 1996; Schellenberg et al, 1992).”
BackgroundFan, Y., Luo, R., Su, L.-Y., Xiang, Q., Yu, D., Xu, L., Chen, J.-Q., Bi, R., Wu, D.-D., Zheng, P., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170594 · Cited by 38
“At the present time, transgenic mouse is the most extensively used model, which had made a significant and valuable contribution for AD research [20, 21, 78].”
Luetjens, C. M., Lankiewicz, S., Bui, N. T., Krohn, A. J., Poppe, M., & Prehn, J. H. M. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00458-9 · Cited by 37
Bunnell, W. L., Pham, H. V., & Glabe, C. G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.48.31947 · Cited by 41
Functional characterization of novel presenilin-2 variants identified in human breast cancers
To, M. D., Gökgöz, N., Doyle, T. G., Donoviel, D. B., Knight, J. A., George‐Hyslop, P. S., Bernstein, A., & Andrulis, I. L. (2006) · Oncogene · doi:10.1038/sj.onc.1209397 · Cited by 37
“In agreement with previous studies (Scheuner et al., 1996; Citron et al., 1997), expression of FAD-linked mutations in PS-2 resulted in a clear increase in the level of secreted Ab(42) peptide, as reflected in a higher Ab(42)/ Ab(40) ratio (Figure 2b).”
BackgroundMethodResultInfluentialOkochi, M., Eimer, S., Böttcher, A., Baumeister, R., Romig, H., Walter, J., Capell, A., Steiner, H., & Haass, C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005254200 · Cited by 40
Rudrabhatla, P., & Pant, H. C. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1243 · Cited by 39
“Similar increases in Aβ42 have been reported in transgenic mice overexpressing FAD presenilin mutants [70] or in FAD brains [71].”
Cavaleri, F. (2015) · Medical Hypotheses · doi:10.1016/j.mehy.2015.10.009 · Cited by 38
Intramitochondrial proteostasis is directly coupled to α-synuclein and amyloid β1-42 pathologies
Lautenschläger, J., Wagner-Valladolid, S., Stephens, A. D., Fernández‐Villegas, A., Hockings, C., Mishra, A., Manton, J. D., Fantham, M., Lü, M., Rees, E. J., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011650 · Cited by 39
Serrano-López, E. M., Bell, K. F. S., Ribeiro‐da‐Silva, A., & Cuello, A. C. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6410 · Cited by 43
“in vitro studies have shown that Aβ fragments can be produced [3,10,31,65,70] and stored [27,31,65,70] in-”
Positional effects of presenilin-1 mutations on tau phosphorylation in cortical plaques
Shepherd, C. E., Gregory, G. C., Vickers, J. C., Brooks, W. S., Kwok, J. B., Schofield, P. R., Kril, J. J., & Halliday, G. M. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.10.008 · Cited by 40
“In PS-1 AD, these protein changes are thought to occur due to abnormal gamma-secretase cleavage of Abeta, and it has been hypothesised that PS-1 may itself be the gamma-secretase enzyme (Citron et al., 1997; De Strooper et al., 1998).”
BackgroundIntraneuronal amyloid β42 enhanced by heating but counteracted by formic acid
Ohyagi, Y., Tsuruta, Y., Motomura, K., Miyoshi, K., Kikuchi, H., Iwaki, T., Taniwaki, T., & Kira, J. (2006) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2006.06.010 · Cited by 39
Vaucher, E., Fluit, P., Chishti, M. A., Westaway, D. A., Mount, H. T. J., & Kar, S. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7915 · Cited by 38
“Human PS1 transgenes with or without Leu3 Val mutation at codon 286 (L286V) were constructed under the control of the prion (PrP) promoter (43), which allowed expression of the transgene in many neuronal types and, to a lesser extent, in systemic tissues (8, 9).”
BackgroundMethodSelf-citationAmyloid β neurotoxicity in the cholinergic but not in the serotonergic phenotype of RN46A cells
Olesen, O. F., Dagø, L., & Mikkelsen, J. D. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00096-5 · Cited by 37
Presenilin Modulates Pen-2 Levels Posttranslationally by Protecting It from Proteasomal Degradation
Crystal, A., Morais, V. A., Fortna, R. R., Carlin, D., Pierson, T. C., Wilson, C., Lee, V. M. ‐., & Doms, R. W. (2004) · Biochemistry · doi:10.1021/bi0361214 · Cited by 40
Shirotani, K., Takahashi, K., Ozawa, K., Kunishita, T., & Tabira, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7730 · Cited by 36
Metabotropic glutamate receptors in superficial laminae of the rat dorsal horn
Jia, H., Rustioni, A., & Valtschanoff, J. G. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19990809)410:4<627::aid-cne9>3.0.co;2-8 · Cited by 164
Why therapies for Alzheimer’s disease do not work: Do we have consensus over the path to follow?
Amtul, Z. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.09.003 · Cited by 39
The secretases of Alzheimer's disease
Wolfe, M. S. (2003) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(03)54011-x · Cited by 35
Van Uden, E., Carlson, G., St. George-Hyslop, P., Westaway, D., Orlando, R., Mallory, M., Rockenstein, E., & Masliah, E. (1999) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1999.0772 · Cited by 32
Self-citationAlzheimer s disease and heparan sulfate proteoglycan
Fukuchi, K.-I. (1998) · Frontiers in Bioscience · doi:10.2741/a277 · Cited by 34
Quantification of sub-femtomole amounts of Alzheimer amyloid β peptides
Potempska, A., Mack, K., Mehta, P. D., Kim, K. S., & Miller, D. L. (1999) · Amyloid · doi:10.3109/13506129908993283 · Cited by 38
Physical and genetic interaction of filamin with presenilin in Drosophila
Guo, Y., Zhang, S. X., Sokol, N. S., Cooley, L., & Boulianne, G. L. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.19.3499 · Cited by 42
Pradier, L., Carpentier, N., Delalonde, L., Clavel, N., Bock, M., Buée, L., Mercken, L., Tocqué, B., & Czech, C. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0212 · Cited by 37
“…of the amyloid peptide, Ab1-42 (42 mino acids), compared to Ab1-40 (40 amino acids) in arrier patients (Scheuner et al., 1996), in transfected ells (Borchelt et al., 1996; Tomita et al., 1997; Xia et al., 997a), and in transgenic mice (Borchelt et al., 1996; itron et al., 1997; Duff et al., 1996).”
BackgroundSecretases as therapeutic targets for the treatment of Alzheimer's disease
Dominguez, D. I., Strooper, B. D., & Annaert, W. G. (2001) · Amyloid · doi:10.3109/13506120109007356 · Cited by 44
Single-Molecule Imaging Reveals Aβ42:Aβ40 Ratio-Dependent Oligomer Growth on Neuronal Processes
Johnson, R. D., Schauerte, J. A., Chang, C.-C., Wisser, K. C., Althaus, J. C., Carruthers, C. J. L., Sutton, M. A., Steel, D. G., & Gafni, A. (2013) · Biophysical Journal · doi:10.1016/j.bpj.2012.12.051 · Cited by 41
Metadata
- Authors
- Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St George Hyslop, P., & Selkoe, D. J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Toronto (CA)
- McLaughlin Research Institute (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1997-01
- Volume
- 3
- Issue
- 1
- Pages
- 67-72
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2081998222
- Cited by
- 1,271
- References
- 28
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 15 · 2023: 20 · 2022: 18 · 2021: 26 · 2020: 29 · 2019: 28 · 2018: 20 · 2017: 20 · 2016: 32 · 2015: 35 · 2014: 38 · 2013: 33 · 2012: 49
- FWCI
- 68.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (64309)
- National Institute on Aging (AG 12749, AG-06173, AG 106812, R01AG012749)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- presenilin mutations, Alzheimer's disease, amyloid-beta 42, presenilin 1, presenilin 2, gain-of-function mutations, transgenic mouse model, beta-amyloidosis, early-onset Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Brain, Cell Line, Enzyme-Linked Immunosorbent Assay, Genetic Vectors, Hippocampus, Humans, Membrane Proteins, Mice, Transgenic, Mutation, Peptide Fragments, Transfection, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.